New Delhi: Days after the World Health Organisation (WHO) put a pause on clinical trials of anti-malaria drug hydroxychloroquine for COVID-19 treatment over safety concerns, the United Nations agency on Wednesday said that trials can resume. Also Read - Now, A Squirrel in US Tests Positive For the Bubonic Plague, Twitter Says '2020 Has No Chill'

“On the basis of the available mortality data… the executive group will communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm,” AFP quoted WHO chief Tedros Adhanom Ghebreyesus as saying.

Hydroxychloroquine is a common anti-malaria drug which is considered effective to slow infections from the Covid-19, SARS-CoV-2 etc.